Skip to content Skip to footer

Emergency Contact

+91 7760396162
+91 8884703308
make an appointment
Sammprada
Sammprada
make an appointment
+91 7760396162
appointment
Sammprada
Close
Best Cancer Treatment Hospitals in Bangalore
  • Home
  • Research & Development

CLINICAL TRIALS

Bootstrap Example
Year in which trial was conducted Indication of Trial Clinical Phase of Trial ( I-IV) Role in Trial (e.g. Investigator, Co-Investigator) Company Code
1991 Prophylaxis against Oral Candidiasis in ALL Patients at KMIO, Bangalore Phase IV Co-investigtor P-fizer India
1995 neutropenic fever of cancer patients at Manipal Hospital, Phase IV Principal Investigator P-fizer India
1997 Comparative study of Erythropoietin with Erythropoietin Omega in chemotherapy induced anemia in cancer pts Phase III Principal Investigator Hindustan Antibiotics Ltd
1998 Observational study of combination of Cisplatinum and Gemcitabine as first line Chemotherapy in non-small cell lung cancer. Principal Investigator IIT
1999 Pilot study of role of topotecan in multiple myeloma resistant to conventional Treatment Principal Investigator IIT
2000 A Study of efficacy and adverse events of durogesic patch in severe cancer pain Principal Investigator IIT
2009 Colon, Colorectal, Breast Cancer Bio-equivalence/ study Co- Investigator Cipla PRC/CRD/33/08
2009 Metastatic Colorectal Cancer II Principal Investigator Nektar 08-PIR-03
2009 NSCLC III Co- Investigator Eli-Lilly H3E-EW-S124
2009 NSCLC III Co- Investigator Pfizer A4021016
2009-2009 Breast Cancer III Principal Investigator Pfizer A6181107
2008-2010 Pancreatic Cancer III Co-Investigator Pfizer A4061028
2008-2009 Breast Cancer II Principal Investigator Siro PPHM0702
2008-2009 Colorectal Cancer III Principal Investigator Pfizer A6181122
2007-2009 Metastatic Breast Cancer II Co-Investigator Roche NO16853D-RG
2007-2008 NSCLC II Principal Investigator Vicus VT1-CAX-001
2007-2008 NSCLC III Principal Investigator Astra Zeneca D4200C00057(ZD6474)
2007-2008 CINV III Co-Investigator GSK NKV(102459)
2007-2008 CINV III Co-Investigator A.P.Pharma C2006-01
2007 GBM III Principal Investigator Clinigene CLG007/BIO005/GLIO/h/R3/2005
2006-2010 G-CSF III Principal Investigator Serum Institute SIILGRASTIM 001
2006-2009 NSCLC IV Principal Investigator Roche MO18109
2005-2007 Breast Cancer II Principal Investigator Pfizer A4061010
2006-2007 Lung Cancer III Principal Investigator Pfizer A8501001
2006-2007 Bronchoalveolar Carcinoma II Principal Investigator Transave,INC TR01-202
2006-2007 Cancer Pain IIb Co-Investigator GSK SB-767905/008
2006-2007 CA Pancreas III Principal Investigator Threshold TH-CR-302
2006-2007 Thrombocytopenia-Solid Tumors II Principal Investigator GSK SB-497115-GR
2005-2006 Breast Cancer with Brain Mets III Principal Investigator GSK EGF 106708
2005-2007 Breast Cancer IV Principal Investigator Roche Bondranate study
2005-2009 Lung Cancer III Principal Investigator Eli-Lilly H3E-MC-JMEN
2005-2006 GM-CSF-Solid Tumors III Co-Investigator Zenotech Zen02/2004
2005-2006 G-CSF II-III Principal Investigator Ranbaxy RX/MACR/2003-32
2005 Metastatic Breast Cancer III Co-Investigator J& J EPO-ANE-3010
2004-2006 Breast Cancer IV Principal Investigator Pfizer A5991002
2004-2007 Breast Cancer(Post Menopausal-Advanced Breast Cancer) IV Principal Investigator Astra Zeneca D5391L00001
2004-2005 Glioblastoma Multiform III Principal Investigator Pfizer EDOAGL-8725-001
2002-2005 Lung Cancer III Principal Investigator Eli-Lilly H7X-MC-JVAA
2002-2005 Breast Cancer II-III Principal Investigator Pharmacia-EORTC 10951
2001-2005 Lung Cancer III Principal Investigator Eli-Lilly H3E-MC-JMEI
2000-2005 Ovarian Cancer II Principal Investigator Eli-Lilly B9E-MC-C163

PUBLISHED ARTICLES

  • Radheshyam Naiket al. CLL and its Variant  – KMIO experience. An analysis of 65 cases of CIL over a period of 9 years. Proceedings of Indo Us CME in Medical Oncology.  Dec 14 – 16 1990.
  • Radheshyam Naiket al. Cutaneous metastases from Bronchogenic Carcinoma. A Case Report JAPI 1992, 40 : 28.
  • Radheshyam Naiket al. Cardiac Tamponade – A rare manifestation of Non-Hodgkin’s Lymphoma. A Case Report, JAPI 1993, 41 : 43 – 45.
  • Radheshyam Naiket al. Ocular Metastases in Breast Cancer . A Case Report JAPI 1995, 43: 577.
  • Radheshyam Naiket al. Published in the Symposium Booklet Frontiers in Oncology-Haematology II at The New York Hospital, Cornell Medical Centre, Oct 14, 1995.
  • Radheshyam Naiket al. Preliminary experience with an implanted Catheter System in Oncology Patients. Ind J Med & Ped Onco 1995, 16: 244 – 47.
  • Radheshyam Naiket al. Patient Management Stratergies: Take Aspergillous Infections seriously. A review Article Ind J Haematol Blood Transf 1995, 13: 143 – 145.

 

  • Radheshyam Naiket al. Canities, Reversal with Chemotherapy. a Case Report JAPI 1995, 43: 577.

 

  • Radheshyam Naiket al. Hypertrophic Osteoarthropathy in Hodgkin’s Diseases. A Case Report  JAPI 1995, Vol. 43 No. 10.

 

  • Radheshyam Naiket al. One of the authors in 1996 ASCO Abstract From.  ASCO Annual Meeting at Philadelphia.  May 18 – 21, 1996.

 

  • Radheshyam Naiket al. Primary colorectal Lymphoma. A Case Report JAPI 1996, Vol. 44 No. 9656 – 57.

 

  • Radheshyam Naiket al. Maintance Recombinant and 2 – b Interferon (Intran) in Multiple Myeloma. ISOG  MM study. One of the authors in the Abstract Form 26th Congress of International Society of Haematology 25 – 29 Aug 1996, Singapore.
  • Radheshyam Naiket al. Renal Oncocytomas – Three Case Reports and review of literature. IJS April 1997, 114 – 1167.

 

  • Radheshyam Naiket al. Cefoperazone – Results of Post Marketing surveillance study in hospitalized patients  and co-relation of  invitro-susceptibilitytests with clinical outcome – Hospital Today, April 1997, Vol.  II No. 7, 21 – 30.
  • Radheshyam Naiket al. Analysis of 10 cases of Primary Central Nervous system Lymphoma over a period of 2 years. Original Article  – JAPI 1997, Col 45, No. 1, 29 – 31.

 

  • Radheshyam Naiket al. “Ramsay Hunt Syndrome in a patient of malignant Granulosa Tumour of Ovary” A Case Report – JIMA – 1997 Col. 45 No. 6, 197 – 200.
  • Radheshyam Naiket al. “Use of implantable Venous ports in Cancer Patients” JAPI 1997,  Vol. 45 No. 7, 593 – 535.

 

  • Radheshyam Naiket al. Cefoperazone – An analysis of results in the Paediatric Population from a post marketing surveillance study in hospitalised patients Indian J Pediatrics. 1998; 65, 89 – 98.
  • Radheshyam Naiket al. Efficacy of IV Human Albumin in preventing chemotherapy induced tiredness – a Pilot clinical trial. Karnataka Journal of Medical Sciences. Oct – Dec 1998, 4, 87 – 91.

 

  • Radheshyam Naiket al. Role of Topotecan in platinum resistant ovarian cancers – A prospective multicenter Licence study – Published in the proceedings of Asia Pacific Cancer Conference at Chennai, 2000.
  • Radheshyam Naiket al. International Journal of Radiation Oncology supplement  Vol.64, No.3S, Nov 1 2012.

 

  • Radheshyam Naiket al. A case of fosphenytoin induced acute cerebellar dysfunction and pituitary bleed causing central diabetes insipdus in a case of AML M2 during allogenic hemopoetic transplantation. International Journal Pharmacol and Clin Sci 2012;1:111-4
  • Radheshyam Naik, Eriat G et al. Adenocarcinoma Colon Masquerading as Acute Leukemia. Journal of Case Reports. 2012 Oct 30;2(2):67-71.

 

  • Govind E, Radheshyam Naiket al. Case of fosphenytoin induced acute cerebellar dysfunc-tion and pituitary bleed causing central diabetes insipidus in a case of AML M2 during allogenic hematopoietic stem cell transplant. Int J Pharmacol and Clin Sci. 2012;1:111-4.
  • Radheshyam Naiket al. Efficacy study of metronomic chemotherapy in metastatic NSCLC – J.Clin Oncol 31,2013 (suppl;  abstr e 19092)

 

  • Srinivasa BJ, Radheshyam Naik et al.Primary Rhabdomyosarcoma of Breast. Journal of Case Reports. 2013 May 5;3(1):130-3.
  • Radheshyam Naik, Rao M et al. “Effects of Yoga on Chemotherapy induced Nausea and Vomiting” which won the Conquer Cancer Foundation Merit award instituted by American Cancer Society and American Society of Clinical Oncology (ASCO – 2013)held between May 31- June 4 2013 at Chicago, Illinois.
  • Radheshyam Naiket al. Online International Interdisciplinary Research Journal, {Bi-Monthly}, ISSN2249-9598, Volume-IV, 30 thNov 2014 Special Issue. With Impact Factor 2.217 ISRA: JIF.

 

  • Radheshyam Naik, Vidya H Veldore et al. Targeted  therapy management in NSCLC patients using cytology; Experience from a tertiary care cancer centre. Submitted to Journal of Targeted Oncology – 2015. Yoga vs Relaxation on Chemotherapy Induced Nausea and Vomiting Outcomes: A Randamized Controlled Trial. J Integr Oncol 2014; 3:1
  • Radheshyam Naik, PKL Nandini et al. Development and Standardization of Jataragni Impairment Checklist(JIC).  International Journal of Multidisciplinary Educational Research. Volume 3, Issue 8(4), August 2014.

 

  • Radheshyam Naiket al, ijmer.in August 2014, Issue: 8(4), Vol: 3, with Impact Factor 2.972 and ICV 5.16 Points. (Index  Copernicus Value).

 

  • Radheshyam Naik, Malur R Usharani et al,Comparison of Yoga vs Relaxation Chemotherapy induced Nausea and Vomiting outcomes: A Randomized Controlled Trial. J Integr Oncol 3:116. Doi : 10.4172/2329-6771.1000116. 2014.

 

  • Radheshyam Naik, Veldore V et al, Genetics and breast cancer–oncologists perspectives. Indian journal of surgical oncology. 2015 Dec 1;6(4):415-9.
  • Radheshyam Naik, Siddesh Southekal et al, Multigene profiling to identify clinically relevant actionable mutations in Indian colorectal cancer patients. Abstract accepted for Poster presentation  UAE Cancer Congress; Oct 2015.

 

  • Radheshyam Naiket al, Role of genetics in breast cancer management – A review article. Sent for publication in Indian Journal of Surgical Oncology on 14th June 2015.
  • Mithua Ghosh, Radheshyam Nayaket al. Clinical utility of PI3K/AKT/mTOR pathway activation in breast cancer: A study in Indian population.  J Clin Oncol 33, 2015 (suppl; abstr e12542).

 

  • Radheshyam Naik, Bhanu LP et al. Breast Metastasis from Adenocarcinoma of Lung: A Case Report. Southeast Asian Journal of Case Report and Review. 2016 Oct 31;5(5):2537-42.
  • Radheshyam Naik, Patel R et al. PAPR Reduction Techniques in OFDM System. International Journal Computer Science of Trends and technology.;2

 

  • Radheshyam Naik, Chatterjee M et al. Incidental Findings in Male Breast Carcinoma: A Genetic Counseling Approach. International Journal of Human Genetics. 2016 Sep 1;16(3-4):120-7.
  • Radheshyam Naiket al. Genetics and Breast Cancer – Oncologists Perspectives , Indian Journal of Surgical Oncology (),1-5 on 16th January 2016.

 

  • Mithua Ghosh, Radheshyam Naiket al. Multigene Profiling to identify clinically relevant actionable mutations in Breast Cancer:  An Indian Study. Abstract accepted for Poster presentation (P6-07-01) and Presented at San Antonio Breast Cancer Symposium 2015. Published in  Cancer Res February 15, 2016.
  • Mithua Ghosh, Radheshyam Naiket al. Comprehensive analysis of BRCA mutation (BRCAm) and other germline mutations  (GRm) with a clinic- pathological association in breast cancer: An  Indian study. Abstract accepted for Abstract accepted for Poster presentation (P6-06-06)and Presented at San Antonio Breast Cancer Symposium 2015. Published in Cancer Res February 15, 2016.

 

  • Radheshyam Naik, Veldore VH et al, Targeted therapy management in NSCLC patients using cytology: Experience from a tertiary care cancer center. Molecular diagnosis & therapy. 2016 Apr 1;20(2):119-23.

 

  • Radheshyam Naik, Bhanu Prakash Lalkota et al. Case Report Breast Metastasis from Adenocarcinoma of Lung: A Case Report 2016 Breast Metastasis from Adenocarcinoma of Lung: A Case ReportDecember 2016.
  • Ethirajan R, Radheshyam Naik et al,Correlation Of Cd34 And Hla-Dr Expression With Clinico-Pathological Profile And Outcomes In Mixed Phenotype Acute Leukemia. Journal of Cancer Research & Therapeutics. 2017 Dec 2;13.

 

  • Radheshyam Naik, B. J. Srinivasa et al. Prospective Analysis of Patients Treated with Chemotherapy in Metastatic Adenocarcinoma of Lung—Single Centre Experience. January 2017, Journal of Cancer Therapy 08(09):838-844, DOI: 10.4236/jct.2017.89073.
  • Radheshyam Naik, Srinivasa BJ et al. KDR gene as a Predictive Biomarker of Response to Regorafenib in Patients with Metastatic Colorectal Cancer (mCRC). J Pharmacogenomics Pharmacoproteomics. 2017;8(173):2153-0645.

 

  • Radheshyam Naik, Bhanu LP et al, Combined DPD and UGT1A1 Mutation in a Single Patient: A Case Report. J Pharmacogenomics Pharmacoproteomics. 2017;8(165):2153-0645.
  • Radheshyam Naiket al, Study of Serum Antiproteinases in young emphysematous patients. Accepted as M.D. Thesis, Mangalore University.

 

  • Radheshyam Naik, Devale TI et al, Role of Intraperitoneal Chemotherapy as the Third-Line Treatment of Epithelial Ovarian Cancer: A Case Report with Literature Review. Indian Journal of Surgical Oncology. 2017 Sep 1;8(3):433-5.

 

  • Badarke GV, Radheshyam Naik et al,Malignant Myelomatous Pleural Effusion With Dissiminated Plasma Cell Myeloma-A Case Repot. Journal of Cancer Research & Therapeutics. 2017 Dec 2;13.

 

  • Radheshyam Naik, Khan MA et al. Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report. Molecular and clinical oncology. 2017 Mar 1;6(3):341-3.

 

  • Srinivasa BJ, Radheshyam Naik et al. Clinical Profile and Results in Cancers Treated with Nivolumab: A Single Centre Study. Open Journal of Immunology, 2018, 8, 107 – 111.
  • Radheshyam Naik, Sapkota S et al, T-cell rich B-cell lymphoma of the breast: A rare case report with emphasis on the role of immunohistochemistry in the diagnosis. Indian Journal of Case Reports. 2018:295-7.

 

  • Radheshyam Naik, Srinivasa BJ et al. Efficacy Study of Metronomic Chemotherapy in Metastatic Triple Negative Breast Cancer and Correlation with VEGF, TSP Levels. Advances in Breast Cancer Research. 2018 Mar 14;7(02):107.

 

  • Radheshyam Naik, Kiran PK et al. Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib. South Asian journal of cancer. 2018 Jul;7(3):170.

 

  • Radheshyam Naik, Vidya VH et al. Molecular profiling in NSCLC: A pilot study to screen for new therapeutic targets.2018.

 

  • Radheshyam Naik, Sapkota S et al Analysis of Use and Outcomes of Peripherally Inserted Central Catheter (PICC-Line) in Hemato-Oncological Patients. Journal of Cancer Therapy. 2018 Jan 4;9(01):35.

 

 

  • Radheshyam Naik, BJ Srinivasa et al. Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience. Clin Med Insights Oncol. 2018 Jun 2018. doi: 10.1177/1179554918782475. Collection 2018. 

 

  • Radheshyam Naik, Srinivasa BJ et al. Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience. Clinical Medicine Insights: Oncology. 2018 Jun 27;12:1179554918782475.
  • Radheshyam Naik, Srinivasa BJ et al.Clinical Profile and Results in Cancers Treated with Nivolumab: A Single Centre Study. Open Journal of Immunology, 2018, 8, 107 – 111.

 

  • Radheshyam Naik, Srinivasa BJ et al. Reversible hypopigmentation with pazopanib. Indian Journal of Medical and Paediatric Oncology. 2018 Oct 1;39(4):519.
  • Radheshyam Naik et al, Primary Hepatic Lymphoma : “A perplexing CT Diagnosis made Easy by 18F-FDG PETCT imaging”Sent to the New England Journal of Medicine. Manuscript ID 15-08672. 2018

 

  • G Lohith, Radheshyam Naiket al. Concomitant Venous Thromboembolism [VTE] with Cancer and its Effect on Survival in Indian Patients. Biomedical Journal Scientific & Technical Research. October 30, 2018 .

 

  • Biju George, Radheshyam Naiket al. A Prospective Observational Multi institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study) : A Real World Scenario from India. Indian Journal of Hematology and Blood Transfusion. ISSN 0971- 4502, DO1 10.1007/s12288- 019- 01173- y. 2019.

 

  • Radheshyam Naik, Vinu Sarathy et al. Impact of MGMT Promoter Methylation as a Prognostic Marker in Patients with High Grade Glioma : A Single – Center Observational Study. Jourrnal of Cancer Therapy,2019,10,806-814.

 

  • Sulav Sapkota, Radheshyam Naik et al. Use of Peripherally Inseerted Central Catheter is integral to supportive care in Hematopoietic Stem Cells Transplantation – A single centre study. Eastern J Med Sci – 2019.

 

  • Radheshyam Naik,, Sheela Mysore Lingaraju et al.  Landscape of Clinically Actionable Mutations in Breast Cancer, International e- conference on cancer research June – 2019. DOI: 10.28991/ICCR-2019-013.

 

  • Radheshyam Naik, Kulkarni Vishal et al, Acute pancreatitis caused by pemetrexed, carboplatin, and gemcitabine in a patient with lung cancer: A rare case report. Indian Journal of Medical and Paediatric Oncology – 2019.

 

  • Radheshyam Naik, Sulav Sapkota et al. Clinical Spectrum of Burkholderia Cepacia Infection in Cancer Patients: A Retrospective Study of an Emerging Disease. Medical Microbiology Reports. Med Microbiol Rep 2019, 2:1.

 

  • Vinu Sarathy, Radheshyam Naik et al,  ‘’ FOLFOX and Capecitabine induced hepatic granuloma mimicking metastasis in a rectal cancer patient.’’ RE : bcr – 2019 – 232628.R2 – BMJ 2020.

 

  • Radheshyam Naik, Sulav Sapkota et al, ‘‘Intra thoracic manifestation in Rosai Dorfman Disease (RDD): A case report with review of literature ’’source : Indian journal of case report 2020.

 

 

 

  • Radheshyam Naik, Sulav Sapkota et al. Solid cancer as second malignancy in primary hematological cancer after conventional Treatment- A single institutional study  .Doi : 18231/j.ijmpo.2020.006.

 

  • Radheshyam Naik, Lalnun Puii et al‘’Survival outcomes of metaplastic breast carcinoma: An Indian tertiary care  center data’’ ASCO 2020.

 

  • Hrishi Varayathu, Radheshyam Naik et al. ‘’Taxane induced pulmonary toxicity in breast cancer ‘’ ASCO 2020.

 

  • Radheshyam Naik, Suhail Sayeed Muftiet al. ‘’ Translational relevance of androgen receptor immunohistochemistry scoring systems for data harmonization in triple negative breast cancer (TNBC) ‘’ ASCO 2020.

 

  • Radheshyam Naik,Thianeshwaran S et al. ‘’ Outcome of locally advanced carcinoma of oesophagus : A single institutional experience ‘’ ASCO 2020.

 

  • Vinu Sarathy, Radheshyam Naik et al. A RARE case of cardiac tamponade in patient with metastatic RCC on pazopanib treatment. Hindawi journal : Clinical case reports in oncology. 2019

 

  • Radheshyam Naiket al. Part of two studies accepted in ASCO 2020- A study of 31 patients with meta plastic breast cancer and taxanes induced pulmonary toxicity.
  • Radheshyam Naiket al. Case report of Isolated bone metastasis in a case of carcinoma stomach published in Journal of cancer research and therapy.

 

  • Radheshyam Naiket al. Case report of Isolated bone metastasis in a case of carcinoma stomach published in Journal of cancer research and therapy.

 

  • Radheshyam Naiket al. Efficacy of Plerixafor for stem cell mobilisation in autologous stem cell transplantation published in Journal of cancer therapy.

 

  • Radheshyam Naiket al. Association of Epstein Barr Virus (EBV) with histomorphological and IHC features of Hodgkin’s lymphoma published in Journal of blood research and hematological malignancy.
  • Radheshyam Naiket al. “Impact of MGMT promoter methylation as prognostic marker in patients with glioma: A single centre observation study” has been accepted as a book chapter in ‘Current topics in medicine and medical research’ by Book Publishers International based in UK.

 

  • Devale Tousif, Radheshyam Naiket al. Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3- Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. August 2020.
  • Hrishi Varayathu, Radheshyam Naiket al. “Ogilvie Syndrome in a Refractory Germ Cell Tumor Treated with Vinblastine, Ifosfamide and Cisplatin Regimen” Karger 2020.

 

  • Radheshyam Naik, Srinivasa Belagutty Jayappa et al. “ Clinical Profile of Carcinoma Breast Patients treated with Trastuzumab: A Single Centre Study.” Scientific Research  DOI: 10.4236/abcr.2020.94009.
  • Radheshyam Naik, Girish Badarkhe et al. “The Efficacy and Safety of Plerixafor in Hematopoietic Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma, Multiple Myeloma, and Hodgkin-Lymphoma Who Failed Mobilization with Granulocyte-Colony-Stimulating Factor Alone: A Single-Center Experience.” Indian Journal of Medical and Paediatric Oncology- 2020.

 

  • Radheshyam Naik, Vinod et al. “An Overview of the Genesis of Preventive Oncology Unit at a Tertiary Cancer Care Hospital in a developing country” The International Journal of Preventive Medicine 2020 .

 

  • Vinod K Ramani, Radheshyam Naiket al. ‘‘ A Narrative Review of the Association between Pesticides, Organochlorines and Breast Cancer : Current Advances and Research Perspectives ’’ International Archives of Public Health and Community Medicine, DOI:10.23937/2643-4512/1710049. 2020.

 

  • Vinod K Ramani, Radheshyam Naiket al ‘‘A narrative review on HPV vaccination among boys and men’’ GJMR 2020.

 

  • Vinod K Ramani, Radheshyam Naiket al ‘‘ Simulation model for breast cancer management in India ’’ GJMR 2020.

 

  • Vinu Sarathy, Radheshyam Naik et al. Lung cancer and COViD-19: a review of risk factors , Patho-physiology and treatment options – Advances in lung cancer 2020

 

  • Vinod K Ramani, Radheshyam Naiket al. Clinico-Pathological profile of lung cancers at an institute from south India – A record based retrospective cohort study. Advances in lung cancer 2020.
  • Mithua ghosh, Radheshyam Naik, Sheela Mysore Lingaraju, Sridhar PS, Shekar Patil, Gopinath KS, Sateesh CT, Krithika Murugan, Srinivas BJ, Bhattacharjee, Nalini Rao, Mahesh B, Roopesh K, Shashidhara HP, Ajay kumar‘‘Landscape of clinically actionable mutations in breast cancer ‘A cohort study’’ – Translational Oncology 2020.

 

  • Vinod K Ramani, R, Shinduja, K P Suresh, Radheshyam Naik‘‘ A Study on the Global Scenario of COVID -19 Related Case Fatality Rate, Recovery Rate and Prevalence Rate and Its Implications for Indis – A Record Based Retrospective Cohort Study ’’- Scientific Research Publishing 2020.
  • Vinod K Ramani, Choudhury Bijit, Sarathy Vinu,Jayappa Srinivas Belagutti, Radheshyam Naik‘‘ Clinicopathological Profile of Lung Cancers at an Institute from South India – A record Based Retrospective Cohort Study ’’ – Scientific Research Publishing 2020.

 

Srinivas BJ, Sridhar PS, Bhanu Prakas L, Radheshyam Naik, Recurrence squamous cell carcinoma treated  with Immunotherapy: A Case Report  JCRT_ 1018_20.  

  • Varayathu H, Sarathy V, Thomas BE, Mufti SS, Sangi L, Thungappa SC, Tripathi P, Radheshyam Naik . Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies. J Cancer Res Ther. 2021 Jan-Mar;17(1):114-121. doi: 10.4103/jcrt.JCRT_910_20. PMID: 33723141

 

SENT FOR PUBLICATIONS

  • Suhail S Mufti, Radheshyam Naiket al, Translational Relevance of Androgen Receptor Positivity in Triple Negative Breast Cancer (TNBC)and the utility of Allred Scoring System for Data Harmonization . Lancet 2019.

 

  • Hrishi V, Radheshyam Net al, A retrospective study on clinical efficacy and safety profile of Nab Paclitaxel and Gemcitabine in pancreatic cancer -Impact of Dose Intensity, a single institute experience. International Journal of Clinical Pharamcy – 2019.

 

  • Thianeshwaran S, Radheshyam N et al. Extraosseous Ewing Sarcoma of axilla in an adult- a rare scenario. Journal of cancer research and treatment. 2019

 

  • Kiran P K , Radheshyam N et al. Overview of multiple primary malignancies- a single institute experience. International journal of cancer. 2019

 

  • Vinu Sarathy,  Radheshyam Naik et al. A case of granulocytic sarcoma presenting as sciatica – Hindawi journal : Clinical case reports in oncology. 2019

 

  • Kiran Pk, Radheshyam Naik et al , Hypersensitivity Reaction to Polymeric Micelle Loaded Paclitaxel without Cremaphor el – a case series. BMC Cancer – 2019.
  • Bhanu P Lalkota, Radheshyam Naiket al.  Prognostic implication of cancer stem cell markers CD44, CD24 and ALDH1 in breast cancer – 2019.
  • Kiran Pk, Radheshyam Naik et al ,Study of Peripheral mono nuclear cells and CD 34 cells as a predictive factor for initiating apheresis in autologous stem cell transplant. – The Lancet Hematology – 2020.
  • Vinu Sarathy, Radheshyam Naik et al. Hematopoeitic stem cell transplant as consolidation for aggressive non hodgkins lymphoma –  Journal of clinical hematology 2020.
  • Sulav Sapkota ,Radheshyam Naik et al. Analysis of Peripherally Inserted Central Catheter (PICC – line) in Cancer patients – A single centre experience . south asian journal of cancer , pubmed.2020
  • Vishal Kulkarni , Radheshyam Naik et al,Analysis of Relapsed / Refractory Hodgkins Lymphoma treated with Autologous Transplantation – A Single Centre Experience’, Indian journal of medical and pediatric oncology ; pubmed 2020.
  • Sulav Sapkota ,Radheshyam Naik et al, Relapsed EBV-negative aggressive NK cell Lymphoma of the orbit and scalp – A Case Report with review of literature.”  Journal of Otorhinolaryngology and Allied Science. 2020
  • Sulav Sapkota,Radheshyam Naik et al ‘‘Acute Leukemia as second malignancy in primary solid cancer after conventional Treatment- A Clinico-pathological Study ’’. Indian journal of pathology and oncology . 2020
  • Sulav Sapkota , Radheshyam Naik et al,  ‘‘Plasmablastic Lymphoma involving Kidney in a HIV patient – A Case Report with review of literature ’’;Indian journal of nephrology ; pubmed 2020.
  • Vinod K. Ramani1, R. Shinduja2, K. P. Suresh2, Radheshyam Naik ,  ‘‘A Study on the Global Scenario of COVID-19 Related Case Fatality Rate, Recovery Rate and Prevalence Rate and Its Implications for India—A Record Based Retrospective Cohort Study ’’  scientific research publishing, Advances in Infectious Diseases, 2020, 10, 233-248 .
  • Vinod K. Ramani , Radheshyam Naik ,  ‘‘A narrative review of the pathophysiology of COVID-19 infection among cancer patients: Current evidence and research perspectives ’’DOI: 10.1002/hsr2.237 , Health Science Reports 2020.
  • Incidence and severity of systemic allergic reactions (SAR) reported with chemotherapeutic (Submitted to ASCO 2021)  

 

  • Relative dose intensity (RDI) of nab-P in gem+nab-P combination in pancreatic cancer treatment and the prognostic role of baseline NLR. (Submitted to ASCO 2021)

 

  • Translational relevance of baseline NLR and LMR ratio in predicting response of EGFR-TKI. (Submitted to ASCO 2021)

 

  • Prognostic subset of metastatic and non-metastatic Luminal B breast cancer (LBBC) subtype based on Ki67 index. (Submitted to ASCO 2021)

 

  • Oxaliplatin induced thrombocytopenia as a consequence of splenomegaly. (Under interactive review in Toxicology Reports)

 

  • Molecular Epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: a single center experience from India. (Under interactive review in Onco targets and therapy)

 

  • Hypermagnesemia in critically ill cancer patients. Molecular and clinical Oncology. Accepted on December 2020.

 

  • Vinod K. Ramani , Radheshyam Naik , Outbreak of Ralstonia mannitolilytica infection at a tertiary care oncology center in South India: A case series’, accepted at Asia Pacific Journal of cancer biology  2020.

        

  • Vinod K. Ramani , Radheshyam Naik , A narrative review of the preventive opportunities in cancer: current status and future prospects’, accepted at Asian Journal of Oncology, 2020.
  • Vinod K. Ramani , Radheshyam Naik , An overview of the genesis of Preventive oncology unit at a tertiary cancer care hospital in a developing Country – a concept Paper’, accepted at International Journal of Preventive Medicine, 2020.

 

 

TRANSLATIONAL MEDICINE AND THERAPEUTICS

Dr. Radheshyam founded the Translational Medicine and Preventive Oncology departments.

The Department of Translational Medicine (TMT) provides services that promote a vibrant translational research and training environment at HCG.

 

Translational Medicine Services

  • Early Phase Clinical Research Unit (CRU)
  • Early Phase Oncology Study Design and Data Management
  • Internal and International Second Opinion with a scientific deep dive into rare and recurrent cases
  • Investigator Initiated Studies / Real-world Research
  • In-vitro and In-vivo non-clinical proof of concept studies / Pharmacology Studies
  • Biomarker Research
  • Electrochemotherapy
  • Scalp Hypothermia
  • Regulatory Guidance and Support
  • Scientific due diligence
  • Clinical Data Analysis
  • Medical and Scientific Writing
  • Research Education and Workforce Development

Focus Areas

  • Translational Oncology – Solid tumours and Hemato-oncology
  • Immuno-oncology
    • Precision immunotherapy
    • Cell based therapies
    • Microbiome Interactions
    • Tumour Microenvironment Interactions
  • Translational Pathology and Digital Pathology
  • Genomic theranostics (Genotype guided cancer therapy)
  • Diagnostics Development and Drug Screening
  • Cancer Infections
  • Preventive Oncology, Community Engagement and Population Science
  • Integrative Oncology
  • Regenerative Medicine
  • Wet Bio repository: To collect patients blood, urine and stool for further studies.

Planned Projects:

  • Doing an extensive analysis on breast cancer with multiple studies on Androgen receptor, Luminal B, Triple Negative, BRCA, Cancer stem cells and Her2.
  • Digital Cytology for screening of cervical cancer in different communities- along with Aindra
  • Development of miRNA profiling tool for predicting the response of immunotherapy- along with Indian Institute of Science Bangalore
  • Tumor derived exosomes in predicting the response of immune checkpoint inhibitors response in lung cancer- along with Transdisciplinary university
  • Investigator initiated trial on sequencing weekly paclitaxel followed by AC regimen in Her2 negative breast cancer.
  • Overall analysis of immune checkpoint inhibitors in our hospital: 160 patients
  • Retrospective study on Taxane induced pulmonary toxicity in breast cancer.
  • Retrospective analysis of TAC versus AC followed by Taxanes in breast cancer.